Impact of Acute HIV Infection and Early Antiretroviral Therapy on the Human Gut MicrobiomeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked how early gut dysbiosis appears after HIV infection and how early antiretroviral therapy affects it. Researchers profiled fecal microbiota using 16S rDNA sequencing. Samples were taken at diagnosis of acute HIV infection, across Fiebig stages 1 to 5, and again after 6 months of therapy. Dysbiotic bacterial taxa were then linked to relevant inflammatory markers to explore a microbiome-inflammation connection.
Who was studied?
The cohort was 52 Thai men who have sex with men, sampled at diagnosis of acute HIV infection. Sampling spanned the very early Fiebig stages 1 to 5 of infection. Seven Thai HIV-uninfected men served as controls. Participants were followed after starting antiretroviral therapy, with fecal samples collected again 6 months later. All were adult men in Thailand.
What were the most important findings?
Comparing acute HIV infection before therapy with uninfected controls showed only a mild dysbiosis. Transition through Fiebig stages 1 to 3 was marked by enrichment of pro-inflammatory bacteria. After therapy, samples showed lower proportions of Bacteroidetes and higher frequencies of Proteobacteria and Fusobacteria members compared with before therapy. Fusobacteria members were positively correlated with levels of soluble CD14 in the post-therapy acute infection samples.
What are the greatest implications of this study?
The results indicate gut dysbiosis begins during early acute HIV infection and is only partly restored by early antiretroviral therapy. Starting therapy early may limit but not fully reverse microbiome disruption. The link between dysbiotic taxa and inflammatory markers suggests altered gut microbiota may connect to systemic inflammation from the earliest infection. The sample is small, all male, and from one country, so the associations need broader confirmation and do not prove causation.